Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 11/20 | 0.82 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.82 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Risedronic Acid SCHEMBL18378 | 0.91 | FDPS (1.00) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL29362587 | 0.91 | FDPS (1.00) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL3771017 | 0.89 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL3170751 | 0.89 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL4989214 | 0.89 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL2115050 | 0.89 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL2115054 | 0.89 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL22720092 | 0.88 | FDPS (0.94) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL22720090 | 0.88 | FDPS (0.94) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| SCHEMBL8165606 | 0.87 | FDPS (0.76) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9693957-B2 | Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-07-04 | — | — | US | disclosed |
| US-9693957-B2 | Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-07-04 | — | — | US | disclosed |
| US-20140234210-A1 | METAL BISPHOSPHONATE NANOPARTICLES FOR ANTI-CANCER THERAPY AND IMAGING AND FOR TREATING BONE DISORDERS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140234210-A1 | METAL BISPHOSPHONATE NANOPARTICLES FOR ANTI-CANCER THERAPY AND IMAGING AND FOR TREATING BONE DISORDERS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2014-08-21 | — | — | US | disclosed |
| US-20120196835-A1 | ENZYME INHIBITING COMPOUNDS AND METHODS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-08-02 | — | — | US | disclosed |
| US-8168437-B2 | Quantitative determination of risedronate in urine by SPE-LC-MS-MS | SANOFI-AVENTIS U.S. LLC (US) | 2012-05-01 | — | — | US | disclosed |
| US-20090320572-A1 | THE QUANTITATIVE DETERMINATION OF RISEDRONATE IN URINE BY SPE-LC-MS-MS | SANOFI-AVENTIS U.S. LLC (US) | 2009-12-31 | — | — | US | disclosed |
| US-7485726-B2 | Process for the preparation of risedronate sodium hemi-pentahydrate | AUROBINDO PHARMA LTD. (IN) | 2009-02-03 | — | — | US | disclosed |
| US-20080260827-A1 | RISEDRONATE COMPOSITIONS AND THEIR METHODS OF USE | BURGIO DAVID ERNEST | 2008-10-23 | — | — | US | disclosed |
| US-20080214505-A1 | Risedronate compositions and their methods of use | HOFFMANN-LA ROCHE INC. | 2008-09-04 | — | — | US | disclosed |
| US-20070173484-A1 | Process for the preparation of risedronate sodium hemi-pentahydrate | AUROBINDO PHARMA LTD. (IN) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173484-A1 | Process for the preparation of risedronate sodium hemi-pentahydrate | PTH1R, PHPT1, HPD | FDPS 61/4885BTN3A1 1592/4885PDE3A 1955/4885 |
| US-20120196835-A1 | ENZYME INHIBITING COMPOUNDS AND METHODS | COASY, FADS2, FDPS | FDPS 3/4885BTN3A1 4124/4885PDE3A 3438/4885 |
| US-20140234210-A1 | METAL BISPHOSPHONATE NANOPARTICLES FOR ANTI-CANCER THERAPY AND IMAGING AND FOR TREATING BONE DISORDERS | SOST, PPIP5K2, PHPT1 | FDPS 1580/4885BTN3A1 1726/4885PDE3A 2301/4885 |
| US-20080260827-A1 | RISEDRONATE COMPOSITIONS AND THEIR METHODS OF USE | SOST, CYP24A1, CYP27B1 | FDPS 849/4885BTN3A1 3946/4885PDE3A 615/4885 |
| US-20080214505-A1 | Risedronate compositions and their methods of use | SOST, CYP24A1, CYP27B1 | FDPS 849/4885BTN3A1 3946/4885PDE3A 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.